

## rufinamide oral suspension (BANZEL)

### Diagnosis Considered for Coverage:

- Seizures associated with Lennox-Gastaut syndrome

### Coverage Criteria:

#### For diagnosis listed above:

- Dose does not exceed FDA label maximum, **and**
- **For patients 2 years and older only:** Inadequate response, intolerable side effect, or contraindication with TWO of the following alternatives: clonazepam (Klonopin), felbamate (Felbatol), lamotrigine (Lamictal), topiramate (Topamax), and either valproate (Depakene) or divalproex (Depakote).

#### For brand-name Banzel oral suspension:

- Meets above coverage criteria for generic, **and**
- Allergic or intolerable side effect to the generic formulation

### Coverage Duration: one year

Effective Date: 6/28/2023